Corbus Pharma

Corbus Pharma Corbus (Nasdaq: CRBP) is connecting innovation to purpose to improve the futures of cancer and obesity patients.

11/18/2025

Tune-in today, November 18th at 4 p.m. GMT for Corbus CEO Yuval Cohen's presentation at the Jefferies Global Healthcare Conference in London. Watch the webcast here: https://bit.ly/4rbDuoT

11/14/2025

Corbus CEO Yuval Cohen, Ph.D. will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th at 4 p.m. GMT. Register for the webcast here: https://bit.ly/4rbDuoT

11/12/2025

“This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. For key corporate and program updates, visit: https://bit.ly/4oBDZql

11/12/2025

Corbus today provided a corporate update and reported financial results for the quarter ended September 30, 2025. For details: https://bit.ly/4oBDZql

11/11/2025

Attending Guggenheim’s Second Annual Healthcare Innovation Conference in Boston? Corbus CEO Yuval Cohen, Ph.D., will present tomorrow, November 12th at 1 p.m. ET. For webcast details: https://bit.ly/4p7Bax7

11/06/2025

Corbus will participate in a number of upcoming investor conferences including Guggenheim’s Second Annual Healthcare Innovation Conference in Boston on Wednesday, November 12th at 1 p.m. ET. For more information: https://bit.ly/43gypRK

Thank you to all who attended our HNSCC KOL event to review and discuss updated data from our Phase 1/2 clinical study o...
10/22/2025

Thank you to all who attended our HNSCC KOL event to review and discuss updated data from our Phase 1/2 clinical study of CRB-701 presented at . For a replay of the event, visit: https://bit.ly/4gN68HX

Corbus presented a poster titled, “Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate C...
10/20/2025

Corbus presented a poster titled, “Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumors” at . View the poster here: https://bit.ly/4hgWZrc

10/19/2025

Dr. Ari Rosenberg, Principal Investigator on the Phase 1/2 clinical study of CRB-701 and Assistant Professor of Hematology and Oncology at the University of Chicago, comments on the unmet need for patients with HNSCC and the updated data from the Phase 1/2 study presented at : https://bit.ly/4qi8SBu

10/19/2025

In the Phase 1/2 study of CRB-701, the 3.6 mg/kg dose generated objective response rate (ORR) of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC. CRB-701 continues to demonstrate a favorable safety and tolerability profile. Learn more about the data presented at : https://bit.ly/4qi8SBu

10/18/2025

“I’m immensely gratified and encouraged by the pace of enrollment and response rate seen in the study to date,” stated Dominic Smethurst, Chief Medical Officer of Corbus. Read about the updated data from our Phase 1/2 clinical study of CRB-701 to be presented tomorrow, October 19th at : https://bit.ly/4qi8SBu

10/18/2025

Updated data from the Phase 1/2 clinical study of CRB-701 as of September 1, 2025 from 167 patients, of whom 122 were evaluable for efficacy, will be presented at tomorrow, October 19th in a poster titled, “Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours” (Poster ). Learn more: https://bit.ly/4qi8SBu

Address

500 River Ridge Drive, Second Floor
Norwood, MA
02062

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 9am - 5:30pm

Telephone

+16179630100

Website

Alerts

Be the first to know and let us send you an email when Corbus Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Corbus Pharma:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier pe*******on and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.